How to Apply to Incyte

11 min read Last updated April 20, 2026 101 open positions
Blake Crosley
Blake Crosley Researched using publicly available information, hiring data, and ATS analysis.

Key Takeaways

  • Incyte is a roughly 2,400-person, four-billion-dollar-revenue biopharma built around JAK inhibitor science, run from Wilmington DE with a European hub in Morges, Switzerland.
  • The company uses iCIMS as its ATS and runs its public career site on the Jibe platform (an iCIMS product). Apply at careers.incyte.com; expect an iCIMS candidate profile, standard parsing behavior, and knockout-question screening.
  • Hiring is concentrated across oncology and inflammation & autoimmunity franchises, plus the supporting R&D, clinical, commercial, medical affairs, operations, quality, regulatory, and IT/analytics functions.
  • Interviews run three to five rounds with cross-functional panels; Director-and-above roles include a formal presentation. Technical depth and data-backed decision-making carry the weight.
  • The strategic backdrop matters for your decision as much as theirs: Jakafi loss of exclusivity is approaching in the latter part of the decade, and Incyte's next chapter depends on pipeline execution — Opzelura growth, povorcitinib, and the broader I&AI build. Evaluate the role with that context in view.
  • Compensation is competitive against a biopharma peer set and negotiable within defensible ranges. Internships and early-career programs exist and are a credible entry path, especially in R&D.

About Incyte

Incyte Corporation is a Wilmington, Delaware-headquartered biopharmaceutical company best known as a pioneer of JAK (Janus kinase) inhibitor science. Founded in 1991 as a genomics company and re-invented in the mid-2000s as a focused drug developer, Incyte grew on the back of ruxolitinib — marketed as Jakafi in the United States for myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease, and as Jakavi outside the U.S. through a long-standing partnership with Novartis. More recently, the company extended the ruxolitinib franchise into dermatology with Opzelura, the first topical JAK inhibitor approved in the U.S. for atopic dermatitis and nonsegmental vitiligo. Today Incyte sits in an unusual strategic spot: it is large enough to feel like an established commercial biopharma, with roughly 2,400 employees worldwide and annual revenue in the four-billion-dollar range, yet small enough that most of its financial future still rides on a concentrated portfolio and an ambitious pipeline rebuild. The company runs two therapeutic franchises in parallel. Oncology remains the historical core, anchored by Jakafi and extended by Monjuvi in B-cell lymphomas, Pemazyre in cholangiocarcinoma, Iclusig in certain leukemias (acquired via the MorphoSys-Constellation transactions), Zynyz in Merkel cell carcinoma, and Niktimvo in chronic graft-versus-host disease. Inflammation and autoimmunity (I&AI) is the growth engine Incyte is betting on for the next decade — Opzelura in dermatology, the povorcitinib oral JAK1 program in hidradenitis suppurativa and vitiligo, and a widening set of earlier-stage assets. Global operations are coordinated between the Wilmington headquarters at 1801 Augustine Cut-Off in Delaware and a European hub in Morges, Switzerland, with additional R&D, commercial, and manufacturing-adjacent footprint across North America, Europe, and Japan. Leadership under chief executive Hervé Hoppenot, who took over in 2014 after leading Novartis Oncology, has emphasized disciplined R&D spending, internal discovery, and selective bolt-on deals rather than transformational M&A. That philosophy shaped a publicly stated goal of launching a series of new medicines between the mid-2020s and 2030 to offset looming Jakafi loss of exclusivity. Candidates evaluating Incyte should understand this context: the company has real science, a profitable commercial base, and a demonstrable track record of approvals, but its next five to seven years will be defined by whether the pipeline can replace Jakafi cash flows on schedule. Roles here are not insulated from that narrative — they are part of executing against it.

Application Process

  1. 1
    Start at careers

    Start at careers.incyte.com, which is Incyte's public job board. The site is operated on the Jibe career-site platform and all applications are processed through iCIMS (incyte.icims.com), so expect the iCIMS candidate experience end to end.

  2. 2
    Filter by location (Wilmington DE, Morges Switzerland, Remote, and a growing set

    Filter by location (Wilmington DE, Morges Switzerland, Remote, and a growing set of country sites), therapeutic area or function, and job family. R&D, Clinical Development, Commercial, Medical Affairs, Operations, Quality, Regulatory, IT/Analytics, and Corporate functions each have their own families.

  3. 3
    Create an iCIMS candidate profile on your first application

    Create an iCIMS candidate profile on your first application. The profile persists across roles — you do not have to re-enter work history every time, but you do need to refresh your resume and tailor the cover letter per posting.

  4. 4
    Upload a resume in

    Upload a resume in .docx or .pdf (text-based PDF, not scanned). iCIMS will parse it into structured fields; always verify the parsed employment history, dates, and education before submitting, because parse errors are the single most common reason qualified candidates get screened out.

  5. 5
    Complete voluntary self-identification (EEO, veteran, disability) and work autho

    Complete voluntary self-identification (EEO, veteran, disability) and work authorization questions. Incyte sponsors work visas for specialized R&D and clinical roles, but sponsorship availability varies by role and level — answer honestly; inaccurate answers are grounds for rescission later.

  6. 6
    Expect screening knockout questions on licensure (for PharmD, RN, MD roles), the

    Expect screening knockout questions on licensure (for PharmD, RN, MD roles), therapeutic experience (for oncology or dermatology commercial roles), and required certifications (GCP, GLP, GMP, Six Sigma depending on function).

  7. 7
    After submission, a talent acquisition partner typically reviews within two to t

    After submission, a talent acquisition partner typically reviews within two to three weeks. Competitive R&D and clinical roles often move faster; commercial roles during a launch cycle can move fastest of all. Silence past four weeks usually means the role moved forward with other candidates.

  8. 8
    If advanced, the first conversation is a 30-minute recruiter screen covering mot

    If advanced, the first conversation is a 30-minute recruiter screen covering motivation, compensation expectations, work authorization, and fit against the specific req. Be ready to explain why Incyte specifically — generic biopharma answers do not land here.

  9. 9
    Hiring manager interview follows, typically 45 to 60 minutes and heavily focused

    Hiring manager interview follows, typically 45 to 60 minutes and heavily focused on scientific or functional depth. For bench science roles, expect to walk through a recent project in detail. For commercial roles, expect account-planning or launch-readiness discussion.

  10. 10
    Panel or loop interviews come next

    Panel or loop interviews come next — commonly three to five interviewers across cross-functional stakeholders. Senior roles (Director and above) almost always include a formal presentation: a scientific talk for R&D, a business case for commercial, a therapeutic-area landscape review for medical affairs.

  11. 11
    References, background check, and drug screen are standard

    References, background check, and drug screen are standard. Offers are typically delivered verbally by the hiring manager with a written follow-up from HR within 48 hours. Negotiation on base, equity, and sign-on is expected — Incyte benchmarks against a biopharma peer set and has room to move, especially for specialized talent.

Resume Tips for Incyte

recommended

Lead with therapeutic-area relevance

Lead with therapeutic-area relevance. If you have hematology, oncology, or dermatology experience, put it above the fold — these are the franchises Incyte is hiring most actively for. Generic pharma experience without TA tie-in reads as replaceable.

recommended

Quantify impact the way a drug developer would read it

Quantify impact the way a drug developer would read it. Instead of 'managed clinical trial operations', write 'led Phase 2 operations for a 240-patient oncology trial across 45 sites in 8 countries, delivering database lock three weeks ahead of plan'. Numbers + scope + outcome.

recommended

Name the molecules, mechanisms, and modalities you have worked on — JAK inhibito

Name the molecules, mechanisms, and modalities you have worked on — JAK inhibitors, bispecific antibodies, ADCs, small molecules, topicals, oral solids — unless covered by confidentiality. Incyte recruiters screen for mechanism familiarity, not just functional titles.

recommended

For R&D roles, list specific techniques and platforms (crystallography, cryo-EM,

For R&D roles, list specific techniques and platforms (crystallography, cryo-EM, in vivo pharmacology models, flow cytometry panels, DMPK assays, specific -omics platforms). iCIMS keyword matching is real; vagueness costs you.

recommended

For clinical development, call out therapeutic areas, phase experience (Phase 1

For clinical development, call out therapeutic areas, phase experience (Phase 1 first-in-human through Phase 4 post-marketing), and regulatory filings you contributed to — INDs, CTAs, NDAs, BLAs, MAAs, sNDAs. Include the agency (FDA, EMA, PMDA, MHRA) where relevant.

recommended

For commercial and medical affairs, highlight launch experience, payer and acces

For commercial and medical affairs, highlight launch experience, payer and access wins, KOL engagement scope, and specific account types (academic medical centers, community oncology, integrated delivery networks, specialty pharmacy). Name brands you supported where disclosure allows.

recommended

For operations, quality, manufacturing, and supply chain, cite regulatory framew

For operations, quality, manufacturing, and supply chain, cite regulatory frameworks (21 CFR Part 210/211, ICH Q7-Q12, EU Annex 1, Schedule M), audits led or supported, and deviation or CAPA work by volume.

recommended

Keep formatting ATS-clean

Keep formatting ATS-clean. Single-column, standard section headers (Experience, Education, Skills, Certifications, Publications), no text boxes, no headers/footers with critical content, no graphical skill bars. iCIMS parses this layout reliably; anything fancier risks losing structure.

recommended

Use

Use .docx when possible. iCIMS parses Word more consistently than PDF, and .docx preserves heading structure that the parser keys off of. If you submit a PDF, generate it from Word rather than design software.

recommended

For senior roles, add a two-to-three-line executive summary at the top covering

For senior roles, add a two-to-three-line executive summary at the top covering years of experience, therapeutic focus, and one signature accomplishment. Recruiters read this first; it determines whether the rest of the resume gets read.

recommended

Publications and patents matter for R&D

Publications and patents matter for R&D. Include a selected list — first author and key collaborations — with DOIs or patent numbers. A separate one-page publication addendum is acceptable and often requested for Principal Scientist and above.

recommended

Do not pad

Do not pad. Incyte interviewers are technical and will notice when a resume bullet does not hold up under three follow-up questions. Every line should be something you can defend in detail.

ATS System: iCIMS (career site powered by Jibe)

Incyte uses iCIMS as its applicant tracking system and serves its public career site through Jibe, which iCIMS acquired in 2019. Candidates land on careers.incyte.com for browsing and search, then complete applications inside the iCIMS candidate portal at incyte.icims.com. iCIMS is one of the most widely deployed ATS platforms in U.S. biopharma — its parsing engine is reasonably forgiving but rewards clean, standard resume structure, and its knockout question logic can eliminate applications before a human ever sees them. The Jibe layer handles the public search experience, SEO, and candidate marketing; the iCIMS layer handles profile storage, screening, workflow routing, interview scheduling, offer generation, and onboarding handoff.

  • Answer knockout questions (work authorization, licensure, years of experience, required certifications) truthfully and at face value. iCIMS routes automatically on these — a wrong answer, even if defensible in conversation, can silently disqualify you.
  • Verify the parsed resume view inside the iCIMS profile before submitting. Job titles, employment dates, and employer names are the fields most often misparsed, and recruiters search on the parsed fields, not the uploaded file.
  • Mirror the exact phrasing of required skills from the job description where it is truthful. iCIMS keyword scoring is literal; 'clinical data management' and 'CDM' are not treated as identical unless both appear.
  • Keep your iCIMS profile up to date across applications. Apply to one role, keep the profile current, and future applications pre-populate cleanly — this is how internal mobility and talent-pool pings also reach you.
  • Use the 'Join Our Talent Community' option if no current req fits. Incyte recruiters do source from the iCIMS talent pool for upcoming roles, especially in Clinical Development and R&D.
  • Do not upload creative, designer, or infographic resumes. iCIMS parsing degrades sharply on multi-column, image-heavy, or non-standard layouts, and biopharma hiring managers expect a conservative presentation anyway.

Interview Culture

Incyte's interview culture is recognizably pharma — structured, technically demanding, and reference-checked — but with a scientific rigor that tilts toward the drug discovery side of the industry rather than the pure commercial side. Expect three to five rounds across a loop, ordered roughly as recruiter screen, hiring manager deep dive, peer and cross-functional panels, and a final with the functional leader or a skip-level. For Director-level and above, a formal presentation is the norm rather than the exception: a 30-to-45-minute scientific talk for R&D, a business case for commercial, a launch readiness or payer landscape review for market access, a cross-TA landscape for medical affairs. Panels are genuinely cross-functional — a clinical development candidate can expect to interview with regulatory, biostatistics, translational medicine, clinical operations, and commercial in the same loop, and any of those interviewers can vote no. Behavioral questioning tracks a light competency model built around scientific rigor, collaboration, decision-making under uncertainty, and patient focus. STAR-format answers work well, but Incyte interviewers push harder on the 'Task' and 'Result' than on the setup — be ready to state the specific decision you made, the data you used to make it, what you would have done differently, and how the outcome was measured. Answers that stay at the summary level without naming molecules, numbers, timelines, and trade-offs tend to draw skeptical follow-ups. Cultural fit is assessed against a stated set of values emphasizing science, integrity, urgency, and respect; in practice this shows up as interviewers probing whether a candidate can disagree on science without being political, and whether they prioritize patient outcomes over internal optics. Two reputational notes are worth absorbing going in. First, Incyte runs a leaner operational footprint than many peers of similar revenue, which means interviewers will test whether you can operate in a role with fewer layers of support than you may be used to. 'How do you handle ambiguity?' here is a real question, not a script. Second, compensation conversations are direct — recruiters will ask for current total comp and target, and are authorized to negotiate within reasonable bands, particularly for specialized R&D and commercial roles. Come with a defensible number and a rationale, not a wish.

What Incyte Looks For

  • Therapeutic-area depth in hematology, oncology, and dermatology — or a credible, specific argument for why your adjacent experience transfers into one of those franchises.
  • Scientific curiosity that survives across a loop. Incyte interviewers talk to each other; a candidate who gives three increasingly shallow answers to the same mechanism question across three rounds gets flagged.
  • Ability to operate in a mid-cap biopharma structure — more accountability per head, fewer dedicated support functions, and more cross-functional exposure than candidates from very large pharma may be accustomed to.
  • Data fluency. Whether you are in discovery, clinical, commercial, or operations, expect to defend decisions with data. 'I felt' is not a completed answer.
  • Urgency paired with rigor. Incyte talks publicly about accelerating pipeline delivery; internally that translates to favoring candidates who can move fast without shortcutting quality, safety, or compliance.
  • Patient-forward framing. The best candidates describe their work in terms of patient impact without making it sound rehearsed.
  • Regulatory and compliance literacy appropriate to the role. GxP fluency for lab and clinical, promotional compliance awareness for commercial, pharmacovigilance awareness for medical — the company operates in a heavily regulated space and expects its people to know the rules.
  • Coachability. Incyte promotes internally and sponsors development, but hiring managers screen for candidates who take feedback without defensiveness. Panels explicitly compare notes on this.

Frequently Asked Questions

What ATS does Incyte use to process job applications?
Incyte uses iCIMS. The public-facing career site at careers.incyte.com runs on Jibe (an iCIMS-owned career site platform), and the application, candidate profile, screening, and interview workflow all sit inside iCIMS at incyte.icims.com. Candidates should prepare a clean, ATS-friendly resume in .docx format, verify the parsed profile before submitting, and answer knockout screening questions truthfully because iCIMS routes decisions off those answers automatically.
Where are Incyte's main offices and which locations hire most?
The corporate headquarters is in Wilmington, Delaware at 1801 Augustine Cut-Off, with the European headquarters in Morges, Switzerland. Wilmington hires the largest share of R&D, clinical development, commercial, medical affairs, and corporate roles. Morges runs the European commercial, medical, and regulatory footprint. Additional roles are posted in other North American, European, and Asia-Pacific country sites as the commercial organization expands.
How long does the Incyte hiring process take?
The typical end-to-end timeline runs four to eight weeks from application to offer for most roles. Recruiter screens happen within two to three weeks of application for competitive files. Hiring manager and panel interviews usually fit into a two-to-three-week window. Senior roles with formal presentations often extend beyond eight weeks because of scheduling across cross-functional panels. If you have not heard back within four weeks of applying, it is reasonable to assume the role has progressed with other candidates.
Does Incyte sponsor work visas?
Incyte sponsors work authorization for specialized roles where the business case supports it — most commonly in R&D, clinical development, and select technical functions. Sponsorship availability varies by role, level, and location, and the job posting or recruiter screen is the authoritative source. Answer work authorization questions in iCIMS truthfully. Misstating authorization status is a standard basis for rescinding an offer later in the process.
What is the risk around Jakafi loss of exclusivity?
Jakafi (ruxolitinib) has been Incyte's dominant revenue contributor for more than a decade, and its U.S. patent protection begins to erode later in the 2020s with full loss of exclusivity approaching the 2028 window. Incyte has stated publicly that it expects to launch a series of new medicines to offset that cash flow transition. Candidates should factor this in realistically: the company is profitable and well-capitalized today, but roles across the organization will be judged over the next several years against how well the pipeline and Opzelura growth replace Jakafi. This is a feature of the job, not a reason to avoid it — but worth naming honestly.
What is Opzelura and why does it matter for hiring?
Opzelura is topical ruxolitinib, the first topical JAK inhibitor approved in the U.S. It is indicated for atopic dermatitis and nonsegmental vitiligo, with continued label and geography expansion work underway. Opzelura is the centerpiece of Incyte's inflammation and autoimmunity franchise and a major driver of commercial hiring — dermatology sales, market access, medical affairs, and patient services teams have all scaled around this brand. A 2024 transaction with Pfizer expanded commercial capabilities for the vitiligo opportunity and signaled continued investment in the I&AI franchise.
What does Incyte's R&D pipeline look like beyond Jakafi?
The pipeline spans oncology (Monjuvi in B-cell lymphomas, Pemazyre in cholangiocarcinoma, Iclusig, Zynyz in Merkel cell carcinoma, Niktimvo in chronic GVHD, plus earlier-stage discovery programs) and inflammation and autoimmunity (povorcitinib, an oral JAK1 program in hidradenitis suppurativa and vitiligo; a next-generation topical JAK program; and additional early-stage I&AI assets). Incyte's R&D strategy favors internal discovery plus selective bolt-on acquisitions rather than transformational M&A.
Who leads Incyte?
Hervé Hoppenot has served as chief executive officer since 2014 and is also chairman of the board. He joined from Novartis Oncology where he led that division globally. His tenure has emphasized disciplined R&D reinvestment, internal discovery capability, measured commercial expansion, and pipeline diversification ahead of Jakafi loss of exclusivity.
What is the interview format at Incyte?
Expect three to five rounds: a recruiter screen, a hiring manager interview, one or more cross-functional panels, and a final with the functional leader or a skip-level. Directors and above typically give a formal presentation — a scientific talk for R&D, a business case for commercial, a therapeutic landscape review for medical affairs. Panels vote, and any panelist can veto; prepare for all interviewers, not only the ones you consider decision-makers.
Does Incyte have internships and early-career programs?
Yes. Incyte runs summer internship programs concentrated in R&D (discovery biology, medicinal chemistry, translational medicine, biostatistics, DMPK), clinical development, commercial, and select corporate functions. Internships are typically posted in the late fall and winter for the following summer cohort on careers.incyte.com. Early-career full-time roles also exist, including Scientist I positions, clinical operations associate roles, and commercial rotational tracks.
What are Incyte's stated values and how do they show up in interviews?
Incyte's culture emphasizes science, integrity, urgency, respect, and patient focus. Interviewers probe these in practical ways: whether you can disagree on data without making it political, whether you prioritize patient outcomes over internal optics, whether you move quickly without cutting compliance corners, and how you handle cross-functional collaboration under time pressure. Behavioral questions in STAR format work well, but interviewers push harder on specific decisions and measurable outcomes than on setup.
How competitive is Incyte's compensation?
Incyte benchmarks against a biopharma peer set that includes mid-cap and large-cap commercial-stage companies, and pay is generally competitive on base, bonus, and equity. Recruiters will ask for current compensation and target; both are negotiable within defensible ranges, especially for specialized R&D, clinical development, and commercial roles. Sign-on bonuses are available to offset forfeited equity. Come with a researched number and a rationale rather than a wish.

Open Positions

Incyte currently has 101 open positions.

Check Your Resume Before Applying → View 101 open positions at Incyte

Related Resources

Similar Companies

Sources

  1. Incyte Corporation — Careers —
  2. Incyte iCIMS Candidate Portal (SSO entry) —
  3. Incyte Corporation — Official Site —
  4. Incyte Corporation — Leadership (Hervé Hoppenot, CEO) —
  5. U.S. FDA — Jakafi (ruxolitinib) prescribing information —
  6. U.S. FDA — Opzelura (ruxolitinib) topical cream approval —
  7. iCIMS acquires Jibe (press release, 2019) —
  8. Incyte — Pipeline —